Neuroscience
Alzheimer's Association Press Release at 0700 hrs EDT on 22 July 2015.
- Alzheimer Disease: Targacept's Failed Tc-1734 Phase 2b Trial
From a Targacept press release:Targacept Phase 2b Clinical Trial in Alzheimer’s Disease Does Not Show Superiority of TC-1734 Over Donepezil July 14, 2014 "Winston-Salem, NC – Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company...
- Alzheimer's Disease: Gammagard Fails
From the company press release: Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease DEERFIELD, Ill., May 7, 2013 - Baxter International Inc. (NYSE:BAX) today announced that its Phase III clinical study of...
- Alzheimer's Disease: Negative Bapineuzumab Findings In Phase Iii Trial
Critical reading for those interested in Alzheimer's clinical trials: first results from the BAP Phase III program. The link includes additional links to a New York Times article and a company press release. From FierceBiotech: UPDATED: Pfizer, J&J...
- Alzheimer's: Bapineuzumab And Solanezumab
Survey shows dim faith in Lilly, Pfizer Alzheimer's drugs Ransdell Pierson | Reuters The Chicago Tribune June 19, 2012 [snip] "Results from the survey of 146 investors were released late on Tuesday by Mark Schoenebaum, a pharmaceutical analyst for...
- Clinical Trials: Solanezumab In Alzheimer's Disease
From Bloomberg: Eli Lilly Shares Rise on Alzheimer’s Drug Hopes By Drew Armstrong and Robert Langreth Dec 6, 2011 [snip] "Solanezumab is an antibody designed to clear protein fragments called beta amyloid that clutter the brains of patients with Alzheimer’s...
Neuroscience
Alzheimer: Clinical Trials Day at the AAIC2015 Conference
Alzheimer's Association Press Release at 0700 hrs EDT on 22 July 2015.
- Longer-Term Analysis of Phase 3 Solanezumab (Lilly) Up to 3.5 Years
- Biomarker Results from Phase 3 Gantenerumab (Roche) Trial
- New Data from Aducanumab (Biogen) Phase 1b Study
Video released by the Alzheimer's Association:
Video from press briefing
Article in The Guardian:
Scientists find first drug that appears to slow Alzheimer's disease
Solanezumab blocks memory loss in patients with mild version of the disease, making it the first medicine ever to slow pace of damage to patients’ brains
Read the article here
- Alzheimer Disease: Targacept's Failed Tc-1734 Phase 2b Trial
From a Targacept press release:Targacept Phase 2b Clinical Trial in Alzheimer’s Disease Does Not Show Superiority of TC-1734 Over Donepezil July 14, 2014 "Winston-Salem, NC – Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company...
- Alzheimer's Disease: Gammagard Fails
From the company press release: Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease DEERFIELD, Ill., May 7, 2013 - Baxter International Inc. (NYSE:BAX) today announced that its Phase III clinical study of...
- Alzheimer's Disease: Negative Bapineuzumab Findings In Phase Iii Trial
Critical reading for those interested in Alzheimer's clinical trials: first results from the BAP Phase III program. The link includes additional links to a New York Times article and a company press release. From FierceBiotech: UPDATED: Pfizer, J&J...
- Alzheimer's: Bapineuzumab And Solanezumab
Survey shows dim faith in Lilly, Pfizer Alzheimer's drugs Ransdell Pierson | Reuters The Chicago Tribune June 19, 2012 [snip] "Results from the survey of 146 investors were released late on Tuesday by Mark Schoenebaum, a pharmaceutical analyst for...
- Clinical Trials: Solanezumab In Alzheimer's Disease
From Bloomberg: Eli Lilly Shares Rise on Alzheimer’s Drug Hopes By Drew Armstrong and Robert Langreth Dec 6, 2011 [snip] "Solanezumab is an antibody designed to clear protein fragments called beta amyloid that clutter the brains of patients with Alzheimer’s...